EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on building a biosimilar business. It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference product. The company was founded in 2000 and is headquartered in Boston, MA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company